Here we report that treatment of prostate cancer cells with M-110 or a structurally unrelated PIM kinase inhibitor SGI-1776 increases the expression of MIG6 RNA and protein and inhibits EGF induced activation of the EGFR and the downstream ERK MAPkinase pathway. The gene discussed is EGFR; the disease is prostate cancer.